1 / 32

Labelling Survey 1999

Labelling Survey 1999. FIP Working Group on Labelling. FIP Working Group on Labelling. Stein Lyftingsmo, Hospital Pharmacy, Norway Oscar Bruce, Pharmacy Information, Ghana Leander Fontaine, Industrial Pharmacy, USA Avi Moshenson, Community Pharmacy, Israel

paul-fleming
Download Presentation

Labelling Survey 1999

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Labelling Survey 1999 FIP Working Group on Labelling Labelling Survey 1999

  2. FIP Working Group on Labelling • Stein Lyftingsmo, Hospital Pharmacy, Norway • Oscar Bruce, Pharmacy Information, Ghana • Leander Fontaine, Industrial Pharmacy, USA • Avi Moshenson, Community Pharmacy, Israel • Jerome A Reinstein, World Self-medication Industry, Great Britain Labelling Survey 1999

  3. Purpose of survey • How is drug labelling done in different parts of the world? Labelling Survey 1999

  4. Distribution • Mail: FIP member organisations • E-mail: FIP-list • E:mail; E-DRUG Labelling Survey 1999

  5. Answers • 58 answers from 46 countries • fax 2 • mail 24 • e-mail 32 Labelling Survey 1999

  6. Countries & population • Survey population 2.751 mill • 46,7% of world population 5.901 mill • India 982 mill - 36% of survey total • USA 274 mill - 10% • Brazil 166 mill - 6% • Russian Federation 147 mill - 5% Labelling Survey 1999

  7. Missing countries >50 mill • China Egypt • Indonesia Iran • Pakistan Ethiopia • Viet Nam Ukraine • Phillipines Labelling Survey 1999

  8. Distribution channels for prescription medicine Labelling Survey 1999

  9. Prescription medicine without prescription • Easy in 14 countries with 60% of survey population. • 7 of these countries with 45% of survey population had market share for pharmacies 90% or higher Labelling Survey 1999

  10. Is ”prescription medicine” an useful or usable termin discussing drug labelling? Labelling Survey 1999

  11. Packaging • Prepack • Bulk • Extemperanous preparations Labelling Survey 1999

  12. Prepack and bulk • 90% or more prepack 22 countries, 584 mill • India 75% prepack • 90% or more from bulk 5 countries, 191 mill Labelling Survey 1999

  13. Labelling • Prescription medicine • Dispensed by pharmacy • As seen by the patient, not as it leaves the manufacturer • Inner package (immediate container) Labelling Survey 1999

  14. Customizing(general question) • Always: 18 countries 750 mill • Never: 11 countries 1.524 mill • 7 of these countries, 1.297 mill had pharmacy market share >90% Labelling Survey 1999

  15. Patient’s name • Prepack (Table 12) • Never 21 countries 1.931 mill • Often 5 countries 130 mill • Always 17 countries 608 mill Labelling Survey 1999

  16. Patient’s name • Bulk (Table 13) • Never 7 countries 1.083 mill • Often 5 countries 401 mill • Always 13 countries 624 mill Labelling Survey 1999

  17. Patient’s nameBulk versus prepack • Bulk slightly better • (better in 3 countries, equal in 20) Labelling Survey 1999

  18. Individual Dosage Instructions • Prepack (Table 14) • Never 8 countries 1.236 mill • Often 10 countries 312 mill • Always 25 countries 1.073 mill Labelling Survey 1999

  19. Individual Dosage Instructions • Bulk (Table 15) • Never 2 countries 983 mill • Often 9 countries 231 mill • Always 12 countries 896 mill Labelling Survey 1999

  20. Individual Dosage Instructions • Bulk versus prepack: • Fairly equal. • Bulk better in 2 countries equal in 19 not as good in 3. Labelling Survey 1999

  21. Generic name • Prepack (Table 17) • Never 2 countries 42 mill • Often 13 countries 686 mill • Always 29 countries 1.958 mill Labelling Survey 1999

  22. Strength(one active ingredient) • Prepack (Table 20) • Never 2 countries 42 mill • Often 8 countries 1.357 mill • Always 34 countries 1.287 mill Labelling Survey 1999

  23. Dosage form • Prepack (Table 20) • Never 1 country 20 mill • Often 8 countries 1.254 mill • Always 34 countries 1.412 mill Labelling Survey 1999

  24. Amount(Volume, or number of tablets) • Prepack (Table 24) • Never 2 countries 42 mill • Often 9 countries 489 mill • Always 33 countries 2.155 mill Labelling Survey 1999

  25. Batch number • Prepack (Table 26) • Never 4 countries 41 mill • Often 7 countries 538 mill • Always 33 countries 2.107 mill Labelling Survey 1999

  26. Batch number • Bulk (Table 27) • Never 11 countries 350 mill • Often 9 countries 1.503 mill • Always 4 countries 194 mill Labelling Survey 1999

  27. Batch number • Bulk versus prepack (Table 28): • Prepack definitely better than bulk better in 15 countries equal in 8 Labelling Survey 1999

  28. Expiry date • Prepack (Table 29) • Never 1 country 21 mill • Often 8 countries 273 mill • Always 35 countries 2.392 mill Labelling Survey 1999

  29. Expiry date • Bulk (Table 30) • Never 7 countries 300 mill • Often 10 countries 131 mill • Always 7 countries 1.616 mill Labelling Survey 1999

  30. Expiry date • Bulk versus prepack (Table 31) • Prepack better than bulk: better in 11 countries equal in 13 Labelling Survey 1999

  31. GSD • Generic name • Strength • individual Dosage instructions Labelling Survey 1999

  32. Stein LyftingsmoHospital Pharmacy of ElverumN-2400 ElverumNorwayTel: +47-6243 8950Fax +47-6243 8955e-mail stein@lyftingsmo.no Labelling Survey 1999

More Related